# A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

> **NCT06372821** · PHASE1 · RECRUITING · sponsor: **University College, London** · enrollment: 10 (estimated)

## Conditions studied

- Alzheimer Disease
- Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)
- Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)
- Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

## Interventions

- **DRUG:** NIO752
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06372821
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06372821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06372821, "A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06372821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*